🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Control vaccine with the adjuvant system.

Found 20 matching trials

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

PHASE1

The purpose of this study is to see if two new malaria vaccines called FMP1...

Status

Completed

Location

WRAIR Clinical Trials Center

Start Date

2001-04

Trial ID

NCT01556945

Treatments Being Tested

FMP1/AS02 RTS,S/AS02 AS02 adjuvant alone Malaria challenge

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV

PHASE2

The purpose of this study is to assess the safety and immunogenicity of M72...

Status

Completed

Location

Wits RHI

Start Date

2020-11-17

Trial ID

NCT04556981

Treatments Being Tested

M72/AS01E Mycobacterium tuberculosis vaccine Placebo

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

PHASE4

This is an open-label, randomized, parallel-controlled clinical trial to ev...

Status

Completed

Location

Jiangsu Provincial Center for Diseases Control and Prevention

Start Date

2022-04-23

Trial ID

NCT05303584

Treatments Being Tested

Ad5-nCoV-IH Ad5-nCoV-IM CoronaVac

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

PHASE3

The study is a randomized, double-blind, placebo-controlled, multicenter, c...

Status

Active Not Recruiting

Location

2201-Gates MRI Investigational Site

Start Date

2024-03-05

Trial ID

NCT06062238

Treatments Being Tested

M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine Placebo

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

PHASE2

This study will assess the safety and immunogenicity of 2 different formula...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-11-15

Trial ID

NCT00397943

Treatments Being Tested

GSK's candidate Mycobacterium tuberculosis vaccine 692342 Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline Control vaccine with the adjuvant system.

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

PHASE1

The proposed study is a Phase 1 study with controlled human malaria infecti...

Status

Completed

Location

Clinical Trials Center, WRAIR

Start Date

2014-08

Trial ID

NCT02174978

Treatments Being Tested

FMP012 with AS01B adjuvant system P falciparum Controlled Human Malaria Infection (CHMI)

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

PHASE1

This study is conducted to assess safety and immunogenicity of GSK's HBsAg ...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-10-04

Trial ID

NCT05561673

Treatments Being Tested

GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg)GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg)

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

EARLY_PHASE1

The purpose of this study is to measure the effect of the Shingrix vaccine ...

Status

Completed

Location

Fran and Earl Ziegler College of Nursing

Start Date

2020-09-01

Trial ID

NCT04523246

Treatments Being Tested

SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)Normal Saline

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

PHASE3

The purpose of this study is to assess the immunogenicity, safety, and reac...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-05-10

Trial ID

NCT02699099

Treatments Being Tested

Vitamin A Candidate Plasmodium falciparum malaria vaccine MR-Vac Stamaril

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

PHASE1

Sub-Saharan Africa is the region most affected by the global Human Immunode...

Status

Completed

Location

Perinatal HIV Research Unit

Start Date

2011-12-19

Trial ID

NCT01418235

Treatments Being Tested

MVA-C + gp140/MF59 MVA-C + gp140/MF59 DNA-C2 + MVA-C DNA-C2 + MVA-C + gp140/MF59

Previous Next